NCT06647927 GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis
| NCT ID | NCT06647927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Policlinico S. Donato |
| Condition | Brugada Syndrome (BrS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2024-12-02 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2024-12-02 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research makes several significant contributions to the field of BrS. It employs advanced genetic sequencing techniques to develop a genetic signature to improve the accuracy and efficiency of BrS diagnosis. The identification of specific biomolecular profiles and genetic signatures enhances our understanding of the syndrome's molecular mechanisms, facilitating targeted therapies and refined risk stratification. These advancements optimize patient care by enabling personalized treatment plans and risk assessment. Overall, this research adds value by advancing diagnostic methods, providing molecular insights, optimizing patient care, and positively impacting public health outcomes in BrS.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Patients affected by Brugada Syndrome * Patients who signs the Informed Consent Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06647927 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brugada Syndrome (BrS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06647927 currently recruiting?
Yes, NCT06647927 is actively recruiting participants. Contact the research team at Giuseppe.Ciconte@grupposandonato.it for enrollment information.
Where is the NCT06647927 trial being conducted?
This trial is being conducted at San Donato Milanese, Italy.
Who is sponsoring the NCT06647927 clinical trial?
NCT06647927 is sponsored by IRCCS Policlinico S. Donato. The trial plans to enroll 350 participants.